

**Amendment to the Claims**

This listing of claims will replace all prior versions and listings of claims in this application:

**Listing of Claims:**

1. (Currently amended) A method of treating Parkinson's disease in a human in need of such treatment comprising: the administration to a human in need of such treatment of an antiparkinson therapeutic amount of ~~an antiparkinson agent selected from the group consisting of an anticholinergic agent;~~ a dopaminergic agent[[:]] , a monoamine oxidase agent [[:]] ~~and amantadine,~~ and an anti-inflammatory effective amount of a selective COX-2 inhibitor.
2. (Cancelled)
3. (Cancelled)
4. to 6. (Cancelled)
7. (Previously presented) A method according to claim 1, wherein the dopaminergic agent comprises a dopamine precursor or a dopamine receptor agonist.
8. (Previously presented) A method according to claim 1, wherein the dopaminergic agent comprises levodopa, bromocriptine, pergolide, pramipexole, cabergoline or ropinorole.
9. (Cancelled)
10. (Cancelled)
11. (Currently amended) A method for the treating Hoehn & Yahr Stage I-III Parkinson's disease, which method comprises administration to a patient in need of such treatment

of an amount of a selective COX-2 inhibitor, ~~and an amount of an anti-parkinsonism agent selected from the group consisting of an anticholinergic agent;~~ a dopaminergic agent[[:]] and a monoamine oxidase agent[[:]] ~~and amantadine~~, such that together they provide effective treatment.

12. (Currently amended) A method of relieving the symptoms of Parkinson's disease, which method comprises administration to a patient in need of such treatment of an amount of a selective COX-2 inhibitor, ~~and an amount of an anti-parkinsonism agent selected from the group consisting of an anticholinergic agent;~~ a dopaminergic agent[[:]] and a monoamine oxidase agent[[:]] ~~and amantadine~~, such that together they provide effective relief.
13. (Currently amended) A method of treating Parkinson's disease, which method comprises administration to a patient in need of such treatment of an amount of a selective COX-2 inhibitor, ~~and an amount of an anti-parkinsonism agent selected from the group consisting of an anticholinergic agent;~~ a dopaminergic agent[[:]] and a monoamine oxidase agent[[:]] ~~and amantadine~~, such that together the agents provide greater relief than that obtained by administration of the antiparkinson agent alone.
14. (Currently amended) A method for ameliorating the progress of Parkinson's disease, which method comprises administration to a patient in need of such treatment of a therapeutically effective amount of a selective COX-2 inhibitor, ~~and an amount of an anti-parkinsonism agent selected from the group consisting of an anticholinergic agent;~~ a dopaminergic agent[[:]] and a monoamine oxidase agent[[:]] ~~and amantadine~~, such that together they provide effective amelioration.
15. (Currently amended) A method for slowing the progress of Parkinson's disease, which method comprises administration to a patient in need of such treatment of a therapeutically effective amount of a selective COX-2 inhibitor, ~~and an amount of an anti-parkinsonism agent selected from the group consisting of an anticholinergic~~

~~agent~~; a dopaminergic agent[[:]] and a monoamine oxidase agent[[:]] ~~and amantadine~~,  
such that together they are effective in slowing the progress of the disease.

16. - 19. (Cancelled)

20. (Previously presented) A method according to Claim 1, wherein the selective COX-2 inhibitor is rofecoxib (VIOXX®).

21. (Previously presented) A method of treating Parkinson's disease in a human in need of such treatment according to claim 1 comprising: the administration to a human in need of such treatment of an antiparkinson therapeutic amount of pergolide, an antiparkinson therapeutic amount of selegiline and an anti-inflammatory effective amount of rofecoxib (VIOXX®).